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Background: BioFreedomTM and BioMatrixTM stents are composed with an identical stent platform and drug, but using different drug carrier 
systems: nonpolymer (NP) or biodegradable polymer (BDP). The aim of this study was to evaluate potential impact of the different carrier systems on 
vascular response to the Biolimus A9-eluting stents (BES).
Methods: In BioFreedom-FIM and STEALTH-I, 43 lesions treated with standard-dose BioFreedom (NP-BES, n=13) or BioMatrix (BDP-BES, n=30) 
underwent volumetric IVUS at 4-6 months (nominal stent size: 2.5 or 3.0 mm). In addition to the standard IVUS parameters, a neointima-free frame 
ratio (number of frames without neointima / total frame number) was calculated to assess gross coverage of struts by IVUS-detectable neointima.
Results: The 2 stent groups showed no difference in vessel or peri-stent plaque changes during follow-up. % Neointimal volume (NIV) and 
maximum cross-sectional narrowing (CSN) were also similar, but with a trend toward greater neointimal suppression in NP-BES. On the other hand, 
NP-BES showed a significantly lower neointima-free frame ratio, indicating greater strut coverage with neointima. Late-acquired incomplete stent 
apposition was rare in both stents (p=0.46).
Conclusion: The first-in-man experience of BioFreedom showed comparable vessel responses to those in biodegradable polymer-based BES. The 
different carrier systems appear to affect overall neointimal coverage in the short term following implantation.
